Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD
Phase 2
Not yet recruiting
- Conditions
- Acute Graft Versus Host Disease
- Interventions
- Drug: CD25 antibody combined glucocorticoid as first-line treatment
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Target Recruit Count
- 20
- Registration Number
- NCT06473909
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Drug: Bispecific antibody-based combined with CAR-T cell therapy
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 27
- Registration Number
- NCT06464185
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia
Not yet recruiting
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-07-11
- Target Recruit Count
- 20
- Registration Number
- NCT06461091
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia, Adult
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Target Recruit Count
- 20
- Registration Number
- NCT06449482
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Phase 2
Recruiting
- Conditions
- Relapse Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Target Recruit Count
- 30
- Registration Number
- NCT06447090
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, China, Tianjin, Tianjin, China
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 21
- Registration Number
- NCT06427330
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
Phase 2
Recruiting
- Conditions
- B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 134
- Registration Number
- NCT06415708
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
Phase 2
Recruiting
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-03-05
- Target Recruit Count
- 53
- Registration Number
- NCT06387121
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Not Applicable
Not yet recruiting
- Conditions
- Acute Myeloid LeukemiaAML
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 184
- Registration Number
- NCT06386302
- Locations
- 🇨🇳
Blood Hospital, Tianjin, Tianjin, China
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
Phase 2
Not yet recruiting
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Target Recruit Count
- 66
- Registration Number
- NCT06367374
© Copyright 2025. All Rights Reserved by MedPath